Meropenem Acs Dobfar

Meropenem, the active ingredient in Meropenem Acs Dobfar, is a carbapenem antibiotic presented as an intravenous solution for intravenous use. It is employed to treat severe bacterial infections in hospitalized adults and children, such as complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired and ventilator‑associated pneumonia, severe sepsis, septic shock, and meningitis.

GNH USA supplies Meropenem Acs Dobfar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Meropenem is a broad‑spectrum carbapenem antibiotic used to manage serious bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: effective eradication of mixed aerobic and anaerobic pathogens, improving clinical outcomes. - Complicated urinary tract infections: rapid bacterial clearance and symptom resolution. - Hospital‑acquired pneumonia: broad coverage against resistant Gram‑negative and Gram‑positive organisms. - Ventilator‑associated pneumonia: high lung tissue penetration for critical care patients. - Severe sepsis and septic shock: bactericidal activity essential for rapid infection control. - Meningitis: penetrates the cerebrospinal fluid to treat central nervous system infections.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Vomiting: occasional episodes during infusion. - Headache: transient and usually resolves. - Rash: mild erythematous skin changes. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: acute hypersensitivity requiring immediate medical intervention. - Clostridioides difficile‑associated diarrhea: severe colitis risk. - Severe neutropenia: marked reduction in white blood cells. - Thrombocytopenia: low platelet count leading to bleeding risk. - Renal toxicity: impaired kidney function in susceptible individuals.

Careful assessment and monitoring are essential when using Meropenem.

- Renal function assessment: adjust dosing in patients with impaired clearance. - Seizure risk monitoring: observe patients with pre‑existing CNS disease. - Allergy review: confirm no history of severe β‑lactam hypersensitivity. - Dose adjustment: modify regimen for pediatric and elderly populations as needed. - Concomitant nephrotoxic drugs: use with caution when combined with other renal‑impacting agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with several medications, requiring vigilance.

Major Interactions (Avoid): - Valproic acid: carbapenems reduce serum valproate levels, risking seizure breakthrough. - CNS depressants: concurrent use may increase seizure propensity. - Aminoglycosides: combined nephrotoxicity potential. - Warfarin: possible alteration of INR, requiring close monitoring. - Probenecid: may increase meropenem plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: monitor renal function and electrolyte balance. - Bacteriostatic antibiotics (e.g., chloramphenicol): potential antagonism. - NSAIDs: increased risk of renal impairment. - Other carbapenems: avoid duplicate therapy. - Immunosuppressants: monitor for infection risk.